Abstract
Palliative care and quality of life are important components of cancer care. Both involve attention paid to improvement of symptoms related to either cancer or cancer therapy. Measurement of quality of life is now a critical element of research into novel therapeutics and new treatment strategies in gynecologic oncology. With introduction of new therapies, either unchanged or improved quality of life with the new therapy versus standard of care is ideal. Outcomes have to demonstrate acceptible quality of life changes. The hope is that with improved attention to palliative care, which is synonymous with supportive care, quality of life is unchanged with cancer therapy. When a patient completes cancer therapy, whether in remission or end-of-life, supportive care and thus palliative care, should be continually addressed by the oncology team.